Eli Lilly Covid-19 antibody obtained emergency clearance from the FDA


Illustration from article titled Eli Lillys Covid-19 Antibody Drug Just Received Emergency Clearance From FDA

Photo: Joe Raedle / Staff (Getty Images)

Drug Proven To Help Prevent Hospitalizations In High-Risk Patients Already With Covid-19 Will Be Widely Available Soon, Thanks To Emergency Clearance From FDA Issued Monday Night For Antibody Treatment Made By Eli Lilly & Co .

The medicine, called bamlanivimab, is a single antibody therapy that must be given by healthcare professionals in a hospital or healthcare setting. In A declaration, the FDA said the drug was “specifically directed against the SARS-CoV-2 spike protein, designed to block the virus from attaching and entering human cells.” “

“The emergency clearance of bamlanivimab by the FDA offers healthcare professionals on the front lines of this pandemic another potential tool to treat patients with Covid-19,” said Dr. Patrizia Cavazzoni, Acting Director of the FDA Center for Drug Evaluation and Research, in release. . “We will continue to assess new data on the safety and effectiveness of bamlanivimab as it becomes available.”

In October, the New England Journal of Medicine published the results of a double-blind, placebo-controlled clinical trial in a small number of patients with mild to moderate Covid-19 symptoms, which found that the treatment measurably reduced the risk of hospitalization and alleviated some symptoms.

The drug Eli Lilly offers doctors the opportunity to start fighting the virus before its progression becomes advanced in high-risk patients. The treatment will complement other remedies that have already been cleared by the FDA, such as the antiviral cocktail remdesivir from Gilead Sciences Inc., which is intended for patients who are already seriously ill with Covi-19.

G / O Media can get commission

The company said the treatment will be provided to patients at no cost and that it is ready to have 100,000 doses of the drug ready to ship within days and will manufacture a million doses by the end of 2020.


Please enter your comment!
Please enter your name here